Navigation Links
Quorum Review IRB Presents on Good Clinical Practice Essentials at MAGI’s 2013 Clinical Research Conference
Date:4/17/2013

Seattle, WA (PRWEB) April 17, 2013

Quorum Review IRB, the industry leader in central IRB services, announces Director of Regulatory Affairs and General Counsel Linda Coleman, JD, CIP, CHC, CHRC, as a presenter at MAGI’s 2013 Clinical Research Conference – East. This year MAGI East will be held in Boston, MA, May 5-8, 2013.

Ms. Coleman’s presentation, “Good Clinical Practice Essentials: What You Won’t Learn from the Regulations,” provides unique insights into timely GCP topics. The presentation covers recent guidance from the FDA as well as inspection and audit findings. Using real-life studies packed with practical information, Ms. Coleman’s workshop lays the groundwork for many topics covered in the meeting. The presentation takes place Sunday, May 5th at 9:30 a.m.-12:00 p.m.

Ms. Coleman has over a decade of legal expertise in clinical trial research and regulatory oversight. She joined Quorum Review in 2007 as the Director of Regulatory Affairs and today continues to serve that role in addition to the role of General Counsel, which she assumed early in 2011. In April 2012, Ms. Coleman was honored by Puget Sound Business Journal as “Outstanding Corporate Counsel for a Small Business” (<1000 employees), recognizing her legal expertise in research matters and contribution to education.

MAGI’s 2013 Clinical Research Conference is one of the fastest growing events in the clinical research industry. The conference offers an exceptional networking environment with over 90 sessions and workshops that provide practical tips in a coherent program for operations, regulatory compliance, contracts and budgets. More information about the 2013 conference is available on the MAGI website.

For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.

About Quorum Review IRB

Quorum Review is an independent institutional review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10634274.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quorum Review IRB to Present “eConsent and the iPad: a Case Study” at Global ACRP Conference
2. Quorum Review IRB Presents “IRB Review of Registries, Databases and Biobanking” at 2013 AAHRPP Conference
3. Quorum Review IRB Launches Site Enrollment Service
4. No Nonsense Muscle Building Review Examining Vince DelMonte’s Workout Program Revealed
5. Best 2013 Virginia Home Security System Companies Reviewed by SecurityPlanet.com
6. Instant Traffic App: Review Examining Travis Stephenson's Automated "Super App" Released
7. Brazil Butt Lift: Review Examining Leandro Carvalho's Workout Program Released
8. Holosync Solution: Review Examining the Centrepointe Research Institute’s Meditation Solution Revealed
9. 2013 NuvaRing Blood-Clotting Allegations Inquiries Eligible for Review by Resource4thePeople Attorneys
10. Fantasy Lover Formula: Review Examining System To Become "Her Fantasy Lover" Released
11. Jacksonsville FL Hearing Aid Reviews Made Available Online to Share the Stories of Local Residents that have Overcome Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Reflections of God’s ... God. “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a ... comfort. , “I believe this a great eye-opener for those searching for answers, ...
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology: